WO2011103413A3 - Taxane pro-emulsion formulations and methods making and using the same - Google Patents

Taxane pro-emulsion formulations and methods making and using the same Download PDF

Info

Publication number
WO2011103413A3
WO2011103413A3 PCT/US2011/025418 US2011025418W WO2011103413A3 WO 2011103413 A3 WO2011103413 A3 WO 2011103413A3 US 2011025418 W US2011025418 W US 2011025418W WO 2011103413 A3 WO2011103413 A3 WO 2011103413A3
Authority
WO
WIPO (PCT)
Prior art keywords
emulsion formulations
pro
same
methods making
taxane
Prior art date
Application number
PCT/US2011/025418
Other languages
French (fr)
Other versions
WO2011103413A2 (en
Inventor
Kiichiro Nabeta
Original Assignee
Teikoku Pharma Usa, Inc.
Techno Guard, Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa, Inc., Techno Guard, Co., Ltd. filed Critical Teikoku Pharma Usa, Inc.
Priority to KR1020127018554A priority Critical patent/KR20120126072A/en
Priority to CN2011800094323A priority patent/CN102762202A/en
Priority to EP11745314.2A priority patent/EP2536407A4/en
Priority to JP2012554053A priority patent/JP2013520435A/en
Priority to IN5888DEN2012 priority patent/IN2012DN05888A/en
Priority to AU2011217951A priority patent/AU2011217951B2/en
Publication of WO2011103413A2 publication Critical patent/WO2011103413A2/en
Publication of WO2011103413A3 publication Critical patent/WO2011103413A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Taxane pro-emulsion formulations are provided. Pro-emulsion formulations are dried powders that include a taxane, oil, surfactant and sugar alcohol. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.
PCT/US2011/025418 2010-02-19 2011-02-18 Taxane pro-emulsion formulations and methods making and using the same WO2011103413A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020127018554A KR20120126072A (en) 2010-02-19 2011-02-18 Taxane Pro-Emulsion Formulations and Methods Making and Using the Same
CN2011800094323A CN102762202A (en) 2010-02-19 2011-02-18 Taxane pro-emulsion formulations and methods making and using the same
EP11745314.2A EP2536407A4 (en) 2010-02-19 2011-02-18 Taxane pro-emulsion formulations and methods making and using the same
JP2012554053A JP2013520435A (en) 2010-02-19 2011-02-18 Taxane pro-emulsion formulation and method for its production and use
IN5888DEN2012 IN2012DN05888A (en) 2010-02-19 2011-02-18
AU2011217951A AU2011217951B2 (en) 2010-02-19 2011-02-18 Taxane pro-emulsion formulations and methods making and using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30631510P 2010-02-19 2010-02-19
US61/306,315 2010-02-19

Publications (2)

Publication Number Publication Date
WO2011103413A2 WO2011103413A2 (en) 2011-08-25
WO2011103413A3 true WO2011103413A3 (en) 2012-01-12

Family

ID=44477026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/025418 WO2011103413A2 (en) 2010-02-19 2011-02-18 Taxane pro-emulsion formulations and methods making and using the same

Country Status (9)

Country Link
US (2) US8569357B2 (en)
EP (1) EP2536407A4 (en)
JP (1) JP2013520435A (en)
KR (1) KR20120126072A (en)
CN (1) CN102762202A (en)
AU (1) AU2011217951B2 (en)
IN (1) IN2012DN05888A (en)
TW (1) TWI438009B (en)
WO (1) WO2011103413A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2595857C2 (en) * 2012-05-31 2016-08-27 Кинки Юниверсити Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
JO3685B1 (en) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012680A1 (en) * 1999-02-26 2002-01-31 Patel Mahesh V. Compositions and methods for improved delivery of lipid regulating agents
US20020041896A1 (en) * 1999-05-27 2002-04-11 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
US20090215882A1 (en) * 2006-01-20 2009-08-27 Eriochem, S.A. Lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
US20090275526A1 (en) * 2006-10-26 2009-11-05 Dash Alekha K Mucoadhesive nanoparticles for cancer treatment

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
FR2678833B1 (en) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS.
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) * 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
DE4208527A1 (en) * 1992-03-17 1993-09-23 Max Planck Gesellschaft LIPOSOMES WITH NEGATIVE EXCESS CHARGE
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
ATE274347T1 (en) * 1992-11-27 2004-09-15 Mayne Pharma Usa Inc STABLE INJECTABLE PACLITAXEL SOLUTION
FR2698543B1 (en) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa New taxoid-based compositions.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
DK0693924T4 (en) * 1993-02-22 2008-08-04 Abraxis Bioscience Inc Process for (in vivo) delivery of biological materials and compositions suitable therefor
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4447770C2 (en) * 1994-08-20 2002-12-19 Max Delbrueck Centrum Process for the production of liposomally encapsulated taxol
DE4440337A1 (en) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
KR100330373B1 (en) * 1996-05-28 2002-11-07 주식회사한국신약 Pharmaceutical composition for injection containing taxol
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
DE69804624T2 (en) * 1997-07-29 2002-09-19 Upjohn Co SELF-TEMPERATURE FORMULATION CONTAINING LIPOPHILE COMPOUNDS
US6281175B1 (en) * 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
ATE267613T1 (en) * 1998-03-05 2004-06-15 Phares Pharm Res Nv MEDICINAL PRODUCTS AND THEIR USE
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
SK17422000A3 (en) * 1998-05-20 2001-09-11 The Liposome Company, Inc. Novel particulate formulations
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
BR0010794A (en) * 1999-05-24 2002-06-04 Sonus Pharma Inc Emulsion-vehicle for drugs with poor solubility
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
CN100376291C (en) * 1999-05-27 2008-03-26 阿库斯菲尔公司 Porous drug matrices and methods of manufacture thereof
TW422706B (en) * 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
US6348215B1 (en) * 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP2003521545A (en) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド Taxane formulation with improved solubility
JP3448006B2 (en) * 2000-03-29 2003-09-16 独立行政法人食品総合研究所 Functional emulsion
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
DE10036871A1 (en) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersions for the formulation of poorly or poorly soluble active ingredients
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
EP1545994B1 (en) * 2002-08-21 2006-11-15 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EA201100069A1 (en) * 2008-07-23 2011-10-31 Бхарат Сирумс Энд Вэксинс Лтд. STABLE INJECTABLE NANO EMULSION OF A DOCETEXELL
CN101428002A (en) * 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 Paclitaxel freeze drying microemulsion for injection and method of producing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012680A1 (en) * 1999-02-26 2002-01-31 Patel Mahesh V. Compositions and methods for improved delivery of lipid regulating agents
US20020041896A1 (en) * 1999-05-27 2002-04-11 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
US20090215882A1 (en) * 2006-01-20 2009-08-27 Eriochem, S.A. Lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
US20090275526A1 (en) * 2006-10-26 2009-11-05 Dash Alekha K Mucoadhesive nanoparticles for cancer treatment

Also Published As

Publication number Publication date
WO2011103413A2 (en) 2011-08-25
JP2013520435A (en) 2013-06-06
TW201141538A (en) 2011-12-01
US8569357B2 (en) 2013-10-29
AU2011217951A1 (en) 2012-07-19
TWI438009B (en) 2014-05-21
IN2012DN05888A (en) 2015-09-18
US20110207803A1 (en) 2011-08-25
US20140088181A1 (en) 2014-03-27
EP2536407A4 (en) 2013-08-14
AU2011217951B2 (en) 2013-07-11
CN102762202A (en) 2012-10-31
EP2536407A2 (en) 2012-12-26
KR20120126072A (en) 2012-11-20

Similar Documents

Publication Publication Date Title
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2013046060A9 (en) Paper and methods of making paper
WO2012033813A3 (en) Compositions for dyeing keratin fibers
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2012051210A3 (en) Mesenchymal stem cells and related therapies
WO2012077120A3 (en) Natural formulations
WO2010089411A3 (en) Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2012014076A3 (en) Liver organoid, uses thereof and culture method for obtaining them
WO2011088323A3 (en) Low-haze transparent conductors
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
WO2012099930A3 (en) Flavonol compositions
WO2012125438A8 (en) Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
WO2013185082A3 (en) Inhibitors of bruton's tyrosine kinase
WO2011139899A3 (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2013130963A8 (en) Compositions and methods for treating type iii gaucher disease
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
WO2012087327A3 (en) Polymer systems
WO2012024350A3 (en) Anti-cancer adenoviruses
WO2010005622A3 (en) Telescoping devices
WO2012024392A3 (en) Compositions comprising paulownin and/or paulownia extracts and uses thereof
WO2012064743A3 (en) Methods for improving heart function
WO2012021707A3 (en) Premature-termination-codons readthrough compounds
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180009432.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11745314

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011745314

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011217951

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 5888/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20127018554

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011217951

Country of ref document: AU

Date of ref document: 20110218

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012554053

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE